KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Cash (2017 - 2025)

Alnylam Pharmaceuticals' Change in Cash history spans 17 years, with the latest figure at $166.0 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 224.03% year-over-year to $166.0 million; the TTM value through Dec 2025 reached $690.2 million, up 348.83%, while the annual FY2025 figure was $690.2 million, 348.83% up from the prior year.
  • Change in Cash reached $166.0 million in Q4 2025 per ALNY's latest filing, down from $376.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $497.7 million in Q3 2022 to a low of -$285.9 million in Q1 2022.
  • Average Change in Cash over 5 years is $58.0 million, with a median of $47.5 million recorded in 2022.
  • Peak YoY movement for Change in Cash: tumbled 249268.18% in 2021, then skyrocketed 2084.58% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$274.3 million in 2021, then rose by 24.6% to -$206.8 million in 2022, then decreased by 6.52% to -$220.3 million in 2023, then skyrocketed by 39.25% to -$133.8 million in 2024, then surged by 224.03% to $166.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Change in Cash are $166.0 million (Q4 2025), $376.9 million (Q3 2025), and $93.6 million (Q2 2025).